Antipsychotic pitfalls: idiopathic intracranial hypertension and antipsychotic-induced weight gain.
Acetazolamide
/ administration & dosage
Adult
Antipsychotic Agents
/ administration & dosage
Depressive Disorder, Major
/ complications
Drug Substitution
Female
Headache
/ diagnosis
Humans
Intracranial Hypertension
/ chemically induced
Obesity
/ complications
Quality of Life
Quetiapine Fumarate
/ administration & dosage
Treatment Outcome
Vision, Low
/ chemically induced
Weight Gain
/ drug effects
drug interactions
drugs and medicines
drugs: psychiatry
neurology (drugs and medicines)
unwanted effects / adverse reactions
Journal
BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291
Informations de publication
Date de publication:
30 Jun 2020
30 Jun 2020
Historique:
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
16
2
2021
Statut:
epublish
Résumé
Idiopathic intracranial hypertension (IIH) is a condition associated with poor vision and headaches that can cause disability and reduced quality of life. The onset of IIH is typically associated with sudden weight gain and obesity, which may be due to first-generation or second-generation antipsychotics. This case involved the use of quetiapine in an obese, 28-year-old woman; she gained significant weight after starting the antipsychotic and later developed headaches and blurred vision. Reducing quetiapine and administering acetazolamide significantly improved her symptoms within 4 weeks. This case reminds physicians to consider IIH as a cause of headache and vision loss in patients who have gained weight after starting or increasing quetiapine.
Identifiants
pubmed: 32606104
pii: 13/6/e236161
doi: 10.1136/bcr-2020-236161
pmc: PMC7328757
pii:
doi:
Substances chimiques
Antipsychotic Agents
0
Quetiapine Fumarate
2S3PL1B6UJ
Acetazolamide
O3FX965V0I
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Arch Neurol. 1982 Aug;39(8):461-74
pubmed: 7103794
Neurology. 1991 Feb;41(2 ( Pt 1)):239-44
pubmed: 1992368
Neurology. 2004 Nov 9;63(9):1737-9
pubmed: 15534272
Arch Neurol. 1990 Mar;47(3):315-20
pubmed: 2310315
J Clin Psychiatry. 2007 Apr;68(4):597-603
pubmed: 17474816
Ophthalmology. 2008 Jan;115(1):221
pubmed: 18166427
Neurology. 2011 May 3;76(18):1564-7
pubmed: 21536635
Neurology. 2008 Feb 19;70(8):634-40
pubmed: 18285538
Arch Neurol. 1993 Jan;50(1):78-80
pubmed: 8418804
J Neurol Neurosurg Psychiatry. 2012 May;83(5):488-94
pubmed: 22423118
Cochrane Database Syst Rev. 2015 Aug 07;(8):CD003434
pubmed: 26250102
J Pediatr. 2013 May;162(5):1084
pubmed: 23452583
J Neuroophthalmol. 2001 Mar;21(1):12-4
pubmed: 11315973
Am J Ther. 2020 Sep/Oct;27(5):e532-e534
pubmed: 31356344
Am J Med. 1992 Oct;93(4):391-5
pubmed: 1415302
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Apr 20;83:55-63
pubmed: 29325867
Neurology. 2002 Nov 26;59(10):1492-5
pubmed: 12455560
Schizophr Bull. 2016 Nov;42(6):1418-1437
pubmed: 27217270
BMJ Case Rep. 2011 Jul 27;2011:
pubmed: 22689727
Neurology. 1998 Apr;50(4):1094-8
pubmed: 9566400
Brain. 1991 Feb;114 ( Pt 1A):155-80
pubmed: 1998880
BMJ. 2010 Jul 07;341:c2701
pubmed: 20610512
Cells. 2019 Oct 29;8(11):
pubmed: 31671770
Obes Rev. 2019 Dec;20(12):1680-1690
pubmed: 31524318
Arch Neurol. 1988 Aug;45(8):875-7
pubmed: 3395261
Expert Opin Drug Saf. 2020 Mar;19(3):295-314
pubmed: 31952459